Skip to main content
Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc. — Investor Relations & Filings

Ticker · COCP ISIN · US19188J4094 LEI · 549300QCJ6RBUJKI7S66 US Manufacturing
Open in API
Filings indexed 536 across all filing types
Latest filing 2026-06-09 Board/Management Inform…
Country US United States of America
Listing US COCP

About Cocrystal Pharma, Inc.

https://www.cocrystalpharma.com/

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company that discovers and develops novel antiviral therapeutics for serious and chronic viral diseases. The company utilizes proprietary structure-based drug design technologies to create antiviral drugs that target the viral replication process. Its development pipeline includes programs targeting influenza, SARS-CoV-2 (COVID-19), norovirus, and hepatitis C. Key candidates in its pipeline include CC-42344, a PB2 inhibitor for influenza A in Phase 2 clinical trials, and CDI-988, an oral pan-viral protease inhibitor for norovirus and coronaviruses that has entered Phase 1 trials.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a U.S. SEC Form 8-K current report, specifically Item 5.02 covering the departure of certain officers and the appointment of a new CEO, with details of compensatory arrangements. This is an announcement of a senior management change rather than a full financial report, proxy, or dividend notice. It falls under the Board/Management Information category.
2026-06-09 English
8-K
Board/Management Information Classification · 90% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act, specifically Item 7.01 Regulation FD Disclosure announcing the appointment of James Sapirstein as Chief Executive Officer. This is an announcement of a change in senior management, which matches the definition for Board/Management Information (Code: MANG).
2026-06-03 English
DEFA14A
Proxy Solicitation & Information Statement
2026-05-27 English
DEF 14A
Proxy Solicitation & Information Statement
2026-05-27 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K “Current Report” filed under the Securities Exchange Act, disclosing a Regulation FD press release. It does not contain substantive financial statements, management discussion, voting results, or other specialized content. It is a general regulatory announcement (8-K), fitting the fallback category for miscellaneous SEC filings.
2026-05-26 English
10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.